

Data Sharing Statement

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. DOI: 10.1056/NEJMoa2034577.

| Question | Authors' Response |
|---|--|
| Will the data collected for your study be made available to others? | Yes |
| Would you like to offer context for your decision? | — |
| Which data? | — |
| Additional information about data | — |
| How or where can the data be obtained? | Upon request through the following website: https://www.pfizer.com/science/clinical-trials/trial-data-and-results |
| When will data availability begin? | Upon request, and subject to review. |
| When will data availability end? | — |
| Will any supporting documents be available? | — |
| Which supporting documents? | — |
| Additional information about supporting documents | — |
| How or where can supporting documents be obtained? | — |
| When will supporting documents availability begin? | — |
| When will supporting documents availability end? | — |
| To whom will data be available? | — |
| For what type of analysis or purpose? | — |
| By what mechanism? | — |
| Any other restrictions? | — |
| Additional information | — |

This statement was posted on December 10, 2020, at NEJM.org.